DK3289080T3 - Genterapi til autosomalt dominante sygdomme - Google Patents
Genterapi til autosomalt dominante sygdomme Download PDFInfo
- Publication number
- DK3289080T3 DK3289080T3 DK16787314.0T DK16787314T DK3289080T3 DK 3289080 T3 DK3289080 T3 DK 3289080T3 DK 16787314 T DK16787314 T DK 16787314T DK 3289080 T3 DK3289080 T3 DK 3289080T3
- Authority
- DK
- Denmark
- Prior art keywords
- autosomal dominant
- dominant diseases
- generation therapy
- therapy
- generation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154966P | 2015-04-30 | 2015-04-30 | |
| PCT/US2016/030475 WO2016176690A2 (en) | 2015-04-30 | 2016-05-02 | Gene therapy for autosomal dominant diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3289080T3 true DK3289080T3 (da) | 2021-11-08 |
Family
ID=57198841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16787314.0T DK3289080T3 (da) | 2015-04-30 | 2016-05-02 | Genterapi til autosomalt dominante sygdomme |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190275168A1 (da) |
| EP (2) | EP3289080B1 (da) |
| DK (1) | DK3289080T3 (da) |
| ES (1) | ES2898917T3 (da) |
| PT (1) | PT3289080T (da) |
| WO (1) | WO2016176690A2 (da) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| ES2731437T3 (es) | 2014-11-21 | 2019-11-15 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| CN109154002B (zh) | 2016-03-01 | 2022-08-30 | 佛罗里达大学研究基金会有限公司 | 用于治疗显性视网膜色素变性的aav载体 |
| IL323024A (en) | 2016-05-20 | 2025-10-01 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide RNAs |
| BR112019000057A2 (pt) * | 2016-07-05 | 2019-04-02 | The Johns Hopkins University | composições e métodos com base em crispr/cas9 para o tratamento de degeneração de retina |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| IT201600102542A1 (it) * | 2016-10-12 | 2018-04-12 | Univ Degli Studi Di Trento | Plasmide e sistema lentivirale contenente un circuito autolimitante della Cas9 che ne incrementa la sicurezza. |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| CN110139654A (zh) * | 2016-11-03 | 2019-08-16 | 优美佳生物技术有限公司 | 用于细胞重编程的方法和组合物 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| AU2018221730B2 (en) | 2017-02-15 | 2024-06-20 | Novo Nordisk A/S | Donor repair templates multiplex genome editing |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US20200172927A1 (en) * | 2017-05-15 | 2020-06-04 | The Trustees Of Columbia University In The City Of New York | Reprogramming metabolism by inhibiting vhl for treatment of neurodegeneration |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3661523A4 (en) * | 2017-08-03 | 2021-08-04 | University of Iowa Research Foundation | TREATMENT METHODS FOR GENETIC HEARING LOSS |
| CA3074466A1 (en) * | 2017-08-28 | 2019-03-07 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating cone-rod retinal dystrophy |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| WO2019066549A2 (ko) * | 2017-09-29 | 2019-04-04 | 주식회사 툴젠 | 망막 기능장애 질환 치료를 위한 유전자 조작 |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| SG11202004527YA (en) | 2017-11-15 | 2020-06-29 | Univ Michigan Regents | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
| MA50877A (fr) * | 2017-11-21 | 2020-09-30 | Bayer Healthcare Llc | Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN108034709B (zh) * | 2017-12-18 | 2021-05-07 | 青岛大学 | Guca1a基因在制备检测视锥细胞营养不良制品中的应用 |
| WO2019183630A2 (en) * | 2018-03-23 | 2019-09-26 | The Trustees Of Columbia University In The City Of New York | Gene editing for autosomal dominant diseases |
| US20210324381A1 (en) * | 2018-04-27 | 2021-10-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Therapeutic genome editing in x-linked hyper igm syndrome |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| CA3102095A1 (en) | 2018-06-01 | 2019-12-05 | University Of Florida Research Foundation, Incorporated | Compositions and methods for treatment of dominant retinitis pigmentosa |
| US12275957B2 (en) | 2018-06-09 | 2025-04-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Next generation designer liver organoids and their methods of preparation and use |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020028717A1 (en) * | 2018-08-01 | 2020-02-06 | University Of Maryland, Baltimore | MODULATION OF mTORC1 ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION |
| CN110857440B (zh) * | 2018-08-23 | 2021-02-19 | 武汉纽福斯生物科技有限公司 | 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 |
| EP3867375A1 (en) * | 2018-10-15 | 2021-08-25 | Fondazione Telethon | Genome editing methods and constructs |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN109456995A (zh) * | 2018-11-08 | 2019-03-12 | 杜以军 | 基因敲除质粒、细胞系及制备方法和应用 |
| US20220089670A1 (en) * | 2018-12-28 | 2022-03-24 | University Of Rochester | Gene Therapy for BEST1 Dominant Mutations |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020176552A1 (en) * | 2019-02-25 | 2020-09-03 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| AU2020310201A1 (en) * | 2019-07-10 | 2022-01-27 | Locanabio, Inc. | RNA-targeting knockdown and replacement compositions and methods for use |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| CN110923333B (zh) * | 2019-12-11 | 2020-09-29 | 湖北省农业科学院畜牧兽医研究所 | 山羊zbp1基因第一内含子内与产羔数关联的单倍型标记及其应用 |
| US20230112568A1 (en) * | 2020-02-28 | 2023-04-13 | The Trustees Of The University Of Pennsylvania | Treating autosomal recessive bestrophinopathies and methods for evaluating same |
| CN111484981B (zh) * | 2020-04-26 | 2021-02-02 | 四川省人民医院 | 一种用于构建视网膜新生血管疾病模型的方法和应用 |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| EP4288541A1 (en) | 2021-02-05 | 2023-12-13 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| EP4323522A1 (en) * | 2021-04-16 | 2024-02-21 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| CN116376980A (zh) * | 2023-04-11 | 2023-07-04 | 爱尔眼科医院集团股份有限公司 | 组合物在矫正基因突变中的应用 |
| KR20250123260A (ko) * | 2024-02-07 | 2025-08-18 | 건국대학교 글로컬산학협력단 | Nr2f1 억제제를 포함하는 안과 질환의 예방 또는 치료용 약학 조성물 |
| CN118421630B (zh) * | 2024-05-20 | 2025-03-11 | 中国医学科学院北京协和医院 | 一种靶向RP1L1基因的sgRNA导向序列及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| ATE239785T1 (de) | 1993-02-12 | 2003-05-15 | Univ Johns Hopkins | Funktionelle domänen der restriktionsendonukleasen aus -i(flavobakterium okeanokoites)(foki) |
| US8551970B2 (en) * | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| GB201004475D0 (en) * | 2010-03-17 | 2010-05-05 | Isis Innovation | Gene silencing |
| MX2015017312A (es) * | 2013-06-17 | 2017-04-10 | Broad Inst Inc | Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas. |
| JP7120717B2 (ja) * | 2013-07-09 | 2022-08-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 多重ｒｎａ誘導型ゲノム編集 |
-
2016
- 2016-05-02 EP EP16787314.0A patent/EP3289080B1/en active Active
- 2016-05-02 US US15/569,920 patent/US20190275168A1/en not_active Abandoned
- 2016-05-02 PT PT167873140T patent/PT3289080T/pt unknown
- 2016-05-02 WO PCT/US2016/030475 patent/WO2016176690A2/en not_active Ceased
- 2016-05-02 ES ES16787314T patent/ES2898917T3/es active Active
- 2016-05-02 DK DK16787314.0T patent/DK3289080T3/da active
- 2016-05-02 EP EP21186523.3A patent/EP4008780A1/en active Pending
-
2024
- 2024-08-05 US US18/794,752 patent/US20250235556A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3289080A4 (en) | 2018-10-03 |
| HK1251615A1 (zh) | 2019-02-01 |
| WO2016176690A3 (en) | 2016-12-01 |
| EP3289080A2 (en) | 2018-03-07 |
| US20190275168A1 (en) | 2019-09-12 |
| WO2016176690A2 (en) | 2016-11-03 |
| EP4008780A1 (en) | 2022-06-08 |
| PT3289080T (pt) | 2021-11-19 |
| ES2898917T3 (es) | 2022-03-09 |
| US20250235556A1 (en) | 2025-07-24 |
| EP3289080B1 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3289080T3 (da) | Genterapi til autosomalt dominante sygdomme | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| EP3291824C0 (en) | ANTIMICROBIAL THERAPY | |
| HUE059662T2 (hu) | Eljárás terápiás immunsejtek hatékonyságának fokozására | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| DK3211071T3 (da) | Fremstillingsfremgangsmåde til retinalt væv | |
| DK3328880T3 (da) | Terapeutiske midler | |
| DK3356313T3 (da) | 2-perfluorhexyloktan til oftalmisk indgivelse | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| DK3262066T4 (da) | Genterapi | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| MA39483A (fr) | Agents thérapeutiques cibles | |
| DK3370760T3 (da) | Plasminogenerstatningsterapi til plasminogenmangel | |
| LT3169328T (lt) | Chinolino dariniai, skirti uždegiminių ligų gydymui | |
| DK3612624T3 (da) | Genterapi | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| EP3317241A4 (en) | THERAPEUTIC INHIBITING COMPOUNDS | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| DK3310432T3 (da) | Indretning til effektiv ikke-invasiv to-trinsneurostimulation | |
| DK3294769T3 (da) | Behandling for multipelt myelom (mm) | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| IL262851A (en) | Combination prime: boost therapy |